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8-methoxypsoralen (8-MOP), activated upon exposure to long-wavelength ultraviolet radia-
tion, is used therapeutically to treat the diseased blood cells of cutaneous T-cell lymphoma
patients. The factors responsible for the efficacy of this therapy are reviewed. Primary among
these are the plasma level of 8-MOP at the time of irradiation and the effective dose of UVA.
8-MOP plasma levels determined in a series ofsix patients demonstrated that thedrug is absorbed
at a highly variable rate (122 ng/ml ± 67). A new liquid form of 8-MOP is absorbed with a
modest increase in plasma levels (170 ng/ml) but with no improvement in the variability (± 163).
An examination of the dose-response relationship between 8-MOP concentration and UVA dose
indicated that properties such as 8-MOP photoadduct formation and PHA response are
proportional to the combined doses of these two factors. A new molecular target for 8-MOP
photomodification, cell membrane DNA, is described.
HISTORY
The curative powers of natural products containing the class of drugs known as
furocoumarins (psoralens and angelicins) have been known to mankind since biblical
times [I]. The ancient Egyptians ingested the leaves ofammi majus, a plant that grew
by the Nile River, to treat depigmented areas of skin. Although 5-methoxypsoralen
was first isolated in 1834, it was not until almost a century later, in 1931, that
Phyladelphy demonstrated that sunlight was a necessary co-factor for the activation of
the compound [2]. In 1948, El Mofty isolated and characterized the active ingredient
of the ammi majus plant, 8-methoxypsoralen (8-MOP). Using the purified compound,
he showed that exposure ofthe skin to sunlight after its ingestion led to repigmentation
[3]. Aaron Lerner and Thomas Fitzpatrick, then at the University of Michigan, were
intrigued by these findings and began their own studies on 8-MOP. Their research
established that 8-MOP could be safely administered to humans and that a relatively
low dose was effective for the treatment of vitiligo [4]. By recording the excitation
spectra of 8-MOP, Lerner, now at Yale, observed that the optimal wavelength for the
activation of 8-MOP was 365 nm, which corresponds to an intense band in the
low-pressure mercury spectrum. In the 1950s, an Italian research team led by L.
Musajo at the University of Padua initiated studies on the molecular aspects of the
biological effects of psoralens after an unpleasant personal experience with the potent
photosensitizing effects of the psoralen-containing fig leaf [5]. These pioneering
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photochemical studies first demonstrated that a 2 + 2 photocycloaddition occurred
between psoralens and pyrimidines in DNA [6]. At the time the characterization of
these DNA reactions provided a satisfactory explanation for the biological effects of
8-MOP and ultraviolet A light (UVA).
In the early 1970s, John Parrish led another Harvard team in the development of
8-MOP and UVA (PUVA: psoralen/ultraviolet A treatment) for the treatment of
psoriasis, a hyperproliferative disease of the skin in which the epidermal cells
reproduce themselves at an accelerated rate [7]. The formation of 8-MOP photoad-
ducts slowed the process and restored the proliferation to near-normal rates. Studies
also suggested at that time that this property appeared to be secondary to the ability of
8-MOP to cross-link DNA [8]. Angelicins, however, which are incapable ofcross-link
formation, also inhibited DNA synthesis [9]. To treat psoriasis effectively, it was
necessary to develop high-intensity lamps so that clinically effective doses could be
delivered in a reasonable time period. Kraemer et al. also showed that T cells
circulating through the skin were affected by PUVA [10].
The success of 8-MOP plus UVA in the treatment of psoriasis led investigators to
test its potential efficacy in other disorders of the skin. In 1979, Gilchrest showed that
PUVA was effective in the treatment of cutaneous T-cell lymphoma (CTCL), an
epidermotropic neoplasm [1 1]. Even though the beneficial effects were only palliative,
the encouraging results stimulated the next quantum leap for 8-MOP and UVA
photochemotherapy. Specifically, Edelson, then at Columbia, reasoned that the direct
exposure ofthe diseased T cells ofCTCL patients to 8-MOP and UVA might enhance
their therapeutic efficacy. In collaboration with scientists at Johnson & Johnson,
Edelson and his colleagues, Gasparro and Berger, developed a system which permitted
8-MOP-containing blood to be irradiated outside the patient's body [12]. In the
first-generation prototype system, six sterile plastic bags connected in series were
sandwiched between rigid plastic water-jacket plates, which were then exposed to
UVA from both the top and bottom. The rigid structure maintained the blood
thickness at 1 mm. Irradiation from both sides enhanced the probability that a given
lymphocyte rising to the surface would encounter a therapeutic dose of UVA. Using
monoclonal antibodies developed by Santella and Gasparro, it was shown that even
though the hematocrit was reduced to approximately 5 percent, the shielding effects of
red blood cells and plasma reduced the efficiency of the psoralen-DNA photoreaction
by nearly two orders of magnitude [13]. Despite this drastic reduction, the doses of
UVA delivered under these conditions were sufficient to induce clinical responses (see
[13]; article by Berger). The use ofpsoralens and UVA to affect T cells directly forms
the basis ofextracorporeal photochemotherapy, which is the focus of this issue.
PSORALEN PHOTOADDUCTS
The furocoumarins are a class oftricyclic aromatic compounds formed by the fusion
of a 2,3 furan bond to the 6,7 coumarin bond. The linear compound that results is
known as a psoralen (Fig. 1, upper diagram). If the 2,3 furan bond is fused to the 7,8
bond of the coumarin, an angular furocoumarin, angelicin, is formed (Fig. 1, lower
diagram). The extended aromatic structure of psoralens is responsible for their ability
to absorb long-wavelength ultraviolet A radiation. Figure 2 shows the UV spectrum of
8-MOP. Absorption bands near 250 and 300 nm are characteristic of all furocouma-
rins. It is interesting to note that the optimal wavelengths for activation of 8-MOP
(that is, 320-400 nm) do not coincide with the absorption peak at 300 nm. In fact,
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FIG. 1. Furocoumarin structures: 8-MOP (upper dia-
gram), angelicin (lower diagram).
irradiation ofpsoralens with 300 nm radiation leads to very efficient photodegradation
of the compound. Various substitutions such as methyl, methoxy, hydroxyl, carbe-
thoxy, and amino groups, when added to the furocoumarin ring, alter DNA binding,
photochemical reactivity, and the specific biological effects ofthese drugs (Table 1). In
general, methyl groups make the psoralen compound less water-soluble but increase its
ability to associate with DNA base pairs by intercalation. A greater degree of
intercalation leads to greater photochemical efficiency for photoadduct formation. For
example, compare the data for 8-MOP and 4'-amino-methyl-4,5',8-trimethylpsoralen
(AMT). The binding constant for AMT is roughly 200 times greater than that for
8-MOP. The biological effectiveness of AMT, as measured by tritiated thymidine
incorporation after mitogen stimulation, is at least an order ofmagnitude greater than
that for 8-MOP. The development of new forms of psoralen which are more
water-soluble and which interact more strongly with DNA could lead to significant
improvements in extracorporeal photochemotherapy.
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TABLE I
Physical Chemical Properties of Psoralensa
Solubility DNA Binding ng/ml for
Compound gg/ml Constant M-' 50% Activityb
8-MOP" 38 770 15
AMT 104 150,000 <1
TMA 3 10,100
'For a more complete listing of psoralen properties, see [35].
bIn combination with 1 J/cm2 UVA in a mitogen response assay
cAbbreviations: 8-MOP, 8-methoxypsoralen; AMT, 4'-amino-4,5', 8-
trimethylpsoralen; TMA, 4,6,4'-trimethylpsoralen
UVA photoactivation of furocoumarins results in the creation of specific excited
states. Molecular orbital calculations have shown that the furocoumarin 3,4 bond
would be expected to be the most reactive position because this is the site ofthe greatest
electron density [14]. In fact, in a solution of 8-MOP and thymine, the most prevalent
photoproduct is the 3,4-monoadduct [15]. In double-stranded DNA, however, the 4'5'
adduct becomes the primary photoproduct (Fig. 3). The change in photoproduct yield
is due to the particular suitability of intercalation sites for photochemical reactions
between the DNA base, thymine, and the psoralen molecule. Intercalation forces cause
the psoralen to be properly oriented for thymine photoaddition when excited by
incident UVA radiation. In addition, the psoralen-base pair association minimizes the
importance of excited-state lifetimes, because the encounter between a photoexcited
psoralen molecule and a reaction partner is no longer diffusion-controlled.
Thus, psoralen derivatives can react at either the 3,4 bond of the pyrone ring or the
4,5 bond of the furan ring. Multiple methyl groups, as in 4'-amino-merhyl-4,5',8-
H
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FIG. 3. Psoralen photoadducts. Upper diagram: 4',5'-monoadduct (left), 3,4-monoadduct
(right); Lower diagram: cross-link.
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trimethylpsoralen (AMT), cause the 4',5'-bond to be the principal site of photoadduct
formation [16]. Furocoumarins capable of reacting at both sites are termed "bifunc-
tional." In double-stranded DNA, these bifunctional compounds can form interstrand
cross-links (Fig. 3). Photoadduct formation is wavelength-dependent. Irradiation of
furocoumarin-DNA solutions with monochromatic wavelengths as long as 400 nm can
lead to photoadduct formation (MA in Fig. 2) with yields being proportional to the
extinction coefficient at a given wavelength. Irradiation with wavelengths in the range,
320-370 nm, leads to the efficient formation ofcross-links (XL in Fig. 2). Wavelengths
in this range are a major component of UVA lamps and overlap strongly with the
absorption spectrum of the 4',5'-monoadduct (Fig. 4). Wavelengths less than 320 nm
cause photoreversal of previously formed adducts and degradation of molecules that
are not intercalated between base pairs.
Angelicins (angular furocoumarins) cannot cross-link DNA because the isomeric
arrangement of their aromatic rings does not permit the necessary alignment with
properly opposed thymines on the two DNA strands. In addition, bulky side groups in
some psoralens such as 3-carbethoxypsoralen block activity at one site and, hence,
these compounds can only form DNA monoadducts (e.g., carbethoxypsoralen) [17].
PARAMETERS AFFECTING EXTRACORPOREAL
PHOTOCHEMOTHERAPY
The impressive clinical effects of 8-MOP and UVA in photomedicine are much
more apparent than the mechanisms by which they are achieved. Cellular DNA
(nuclear, mitochondrial, and cell membrane) may be the targets of 8-MOP and UVA.
In addition, the combination of 8-MOP and UVA may alter enzymes, receptors, and
membrane components. Affecting these structures could alter how a cell is processed
by the immune system. Whatever the ultimate mechanism for the efficacy of
photopheresis, there remains one inescapable conclusion, 8-MOP and UVA act in
concert to produce therapeutic effects. For the treatment to be optimally effective,
substantial levels of 8-MOP must be present and an effective dose of UVA must be
delivered to the 8-MOP-containing cells.
HPLCAnalysis of8-MOP in Plasma
Samples are obtained from patients in two ways: either by venipuncture or by direct
removal from the photopheresis collection bag. In either case, the specimen is then
583GASPARRO ET AL.
centrifuged at 2,000 rpm for ten minutes to obtain a plasma sample that is free ofany
sediment. For each I ml of plasma to be analyzed, 1.25 ,tL [3H]8-MOP (Amersham,
2.6 ng/,uL) is added as an internal standard. In 1986 as the use of photopheresis
became more widespread, our laboratory developed the more efficient solid-phase
extraction method (SPE) for the isolation of 8-MOP from plasma samples [18].
Existing methods for the isolation of 8-MOP from plasma involved extraction with
organic solvents (e.g., hexane or benzene), followed by evaporation to re-concentrate
the sample and then resuspension in a solvent suitable for reversed-phase HPLC
analysis. This protocol required two hours to prepare HPLC-ready samples (five
specimens in duplicate). In the SPE method, on the other hand, the multi-step organic
extraction method was replaced with a single-step extraction using a solid-phase
extraction cartridge. In essence, thesecartridges are "mini"-HPLC columns in which a
vacuum is used to apply the sample and to draw the eluting solvent through the
"mini-column." The columns are first "activated" with 10 ml HPLC-grade methanol
and then primed for sample application with 10 ml PBS; 1.00 ml ofplasma containing
the [3H]8-MOP internal standard is then applied. HPLC-interfering proteins and salts
are removed with a 10 ml PBS wash. The 8-MOP is then eluted byapplication ofa 1.00
ml 70 percent methanol-water solution. The specimen is next analyzed by two
independent methods. First, to assure that complete recovery has been achieved,
duplicate samples of the eluted specimen are assayed by liquid scintillometry. Second,
each sample is analyzed by reversed-phase HPLC. 200 ,uL is applied to a reversed-
phase phenyl column (4.6 mm x 15 cm). Using a mobile phase consisting of50 percent
acetonitrile and 50 percent 0.05 M ammonium acetate (pH 4.6), the column eluant is
monitored at 300 nm. Under these conditions, 8-MOP elutes at 265 seconds. A typical
chromatogram is shown in Fig. 5 (left panel). The peak area is used to compute the
8-MOP concentration in the plasma sample. In the right panel of Fig. 5, the ultraviolet
spectra ofthe 8-MOPcontaining peak (lower) and a presumed metabolite (upper) are
shown.
In the photopheresis procedure, several centrifuge cycles are used to obtain fractions
for exposure to UVA. Incremental volumes of plasma and white blood cells are
obtained over a 90-minute period during a typical procedure. Figure 6 shows that the
8-MOPconcentration increases with each additional plasma fraction. Once addition of
plasma is discontinued, there is no further increase in 8-MOP concentration. It is also
important to note that subsequent addition of white cells alone does not appreciably
dilute the 8-MOP and that the subsequent exposure to 90 minutes of UVA does not
photodegrade the 8-MOP.
8-MOPAbsorption
8-MOP and UVA acting synergistically are responsible for the clinical efficacy of
photopheresis. In the initial development of 8-MOP-UVA phototherapy for psoriasis,
the dose of UVA required for clinical efficacy was unequivocally demonstrated. Clear
dose-response relationships between potency and the amounts of UVA and 8-MOP
have been demonstrated in cellular systems (see below). It is assumed that a similar
relationship exists in vivo. Thus, physicians administering PUVA routinely use devices
to monitor and adjust the UVA doses delivered to patient skin. It is equally important
to measure the amount of 8-MOP present in the target tissue. Two factors must be
addressed in photopheresis. One is the individual ability ofa patient toabsorb thedrug,
and the second is the time at which plasma fractions are added to the collection bag
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during photopheresis. In Fig. 7, the absorption characteristics of two forms of 8-MOP
(crystalline and liquid) are illustrated for five individuals. Two of these curves are
prototypical. Curve A illustrates the rapid absorption of oxsoralen ultra. In two other
individuals, however, the oxsoralen ultra did not demonstrate such characteristics
(curves B and C). Curves D and E show the kinetics that are characteristic of
crystalline 8-MOP, namely, a relatively broad absorption requiring two to three hours
to reach a maximum level between 100 and 200 ng/ml. Prior to the availability of
liquid 8-MOP, we had analyzed more than 400 samples and found an average 8-MOP
level of 122 ng/ml (±67, with a range of 0 to 440 ng/ml). The samples were always
obtained from patients two hours after ingestion of the capsules which had been taken
one half hour before eating a light breakfast. Even under these controlled conditions,
intra-individual variation was quite pronounced (Fig. 8). On any given day of
treatment there was a significant probability that the patient could have a sub-optimal
level of 8-MOP present in his or her plasma. Oxsoralen ultra demonstrated a similar
pattern in a series of 27 patients: the average level was 170 ng/ml (± 163, with a range
of 0 to 591 ng/ml). Although the average 8-MOP level was somewhat greater in the
patients who ingested the ultra form, the values are distributed over a very wide
range.
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FIG. 8. Intra-individual variation in 8-MOP plasma levels.
In a small percentage of patients who ingest 8-MOP (either form) for the first time,
the first-pass effect is observed [19]. This effect is a phenomenon in which first
exposure to a drug induces a high level of liver activity that effectively prevents any
significant level of accumulation in the plasma. In the vast majority of these patients,
the second ingestion ofthe drug leads to normal or near-normal levels; however, a small
proportion never achieve the normal levels or, ifthey do, much higher doses ofthe drug
are required. If the patients tolerate the ingestion of the drug (minimal nausea, for
example), there would appear to be no problem with these increased doses.
Many investigators have attempted to elucidate the physiological parameters
underlying the variable absorption of 8-MOP [20]. The absorption data for the two
forms of 8-MOP indicate that the actual physical formulation of the drug, crystalline
or liquid, has very little effect on the ultimate bioavailability of the drug. A simple
chemical principle provides the explanation. The water solubility of 8-MOP is very
low 38 ,ug/ml [211. A typical patient may ingest 40 mg ofthe drug. Ifall ofthis drug
dissolved instantly, it would lead to a stomach concentration of 40 mg in 500 ml of
gastric contents (80 ,ug/ml). This quantity is almost twice its solubility. Thus, once in
the stomach, the drug is expected to do what is thermodynamically impossible. One
could argue that the ultimate concentration might be determined by the total volume
of fluid compartments of the body. In a 70 kg, adult, 60 percent ofthe body weight, or
40 liters, is an approximation of the sum of plasma water, interstitial fluid, and
intracellular fluid. The volume of distribution (Vd) of a drug is computed by dividing
the total amount of the ingested drug by the plasma concentration. Using a drug dose
of 40 mg of 8-MOP (0.6 x 70) and a plasma level of 120 ng/ml, Vd would be greater
than 300,000 ml, which means that very low concentrations of 8-MOP are expected to
be found in the blood [19].
Furthermore, one must contend with the reality of the kinetics of the solubility
process. To gain an appreciation of this process, a single oxsoralen ultra capsule was
added to 500 ml of distilled water (at pH 3). To mimic any possible role of gastric
agitation, the mixture was stirred gently. Complete dissolving of the contents of the
capsule (10 mg) would yield a concentration of 20 ,g/ml (10 mg in 500 ml). TheGASPARRO ET AL.
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FIG. 9. Dissolution ofoxsoralen ultra.
results of this experiment are portrayed in Fig. 9. The solution started out at room
temperature, but with stirring the temperature gradually increased to 32°C over the
first 30 minutes. To measure the amount of 8-MOP present, 1 ml samples were taken
at the points in time indicated in Fig. 9 and immediately centrifuged; 50 ,uL was then
applied to a phenyl reversed-phase column and analyzed as described above. The
capsule did not rupture until 68 minutes had elapsed. At that point, the 8-MOP
concentration was 4.6 ,ug/ml. Since it was anticipated that, once the capsule was open,
the 8-MOP might rapidly dissolve, another sample was taken at 75 minutes, at which
point the concentration was 7.5 ,utg/ml. Close visual inspection of the solution at this
time revealed that it consisted of a suspension of small crystals. Stirring for another
145 minutes did lead to a final concentration of .~ 14 ,ug/ml, which was still 30 percent
below the expected value. The 8-MOP, which had been completely solubilized within
the capsule, precipitated once it was exposed to an aqueous environment. Visual
inspection showed that constant stirring led to virtually complete dissolution. When the
solution was allowed to sit without stirring until the next day and then tested, however,
the concentration had dropped to 5.1 ,utg/ml. To test whether the insoluble material
could be dissolved more rapidly, the solution was heated to 50°C and tested for its
concentration at half-hour periods (indicated as TI, T2, and T3 in Fig. 9). Even under
these highly idealized conditions, 90 minutes was required to redissolve the 8-MOP. In
a separate trial, the contents of another capsule dissolved instantly in absolute
ethanol.
Thermodynamics and kinetics are thefactors governing the dissolution of8-MOP
and, no matter how the drug is prepared in a capsule, the bottom line is that it is an
extremely insoluble material and hence will always be absorbed in an unpredictable
nianner. From this perspective, it is easy to see how depending on stomach contents,
patient health, and perhaps a myriad ofother parameters, a patient could end up with
very different blood levels on different days.
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Effective UVA Dose During Photopheresis
The presence of red blood cells and plasma lead to a significant attenuation of the
UVA dose that is delivered to lymphocytes during photopheresis. DNA treated with
100 ng/ml 8-MOP 1 J/cm2 UVA results in the formation of 55 adducts per million
bases. Iflymphocytes suspended in PBS are treated with the samedoses of8-MOP and
UVA, 4 adducts per million bases are formed-nearly a fourteenfold reduction in
photoadduct yield. If red blood cells are present, there is another sixfold reduction in
adduct formation (-I adduct per million bases). In vitro studies of lymphocytes
treated with 8-MOP and UVA showed that the formation of I adduct per million bases
correspond to an effective UVA dose of 1-2 j/cm2.
The in vitro dose-response effects of 8-MOP and UVA on lymphocytes are
summarized in Fig. 10, in which the various properties are plotted versus the combined
doses of 8-MOP (in ng/ml) and UVA (in j/cm2). Gasparro et al. have demonstrated
that tritiated thymidine incorporation depended only on this product [22]. These data
clearly indicate that the nuclear processes represented by tritiated thymidine incorpo-
ration (TdR in Fig. 10) are completely suppressed when the combined doses of 8-MOP
and UVA reach 50. Another nuclear process for which there is a similar dose-response
effect is the repair of 8-MOP photoadducts and the recovery of cells after 8-
MOP/UVA treatment [Goldminz D, et al: manuscript in preparation]. The effects of
8-MOP and UVA on cell viability (TBE) are affected to the same extent only when the
combined doses of 8-MOP and UVA reach 300-400. Trypan blue exclusion provides a
measure of membrane integrity. Thus, the dose-response curves shown in Fig. 10
correspond to two extreme processes. In one case, low concentrations of 8-MOP and
UVA induce relatively few 8-MOP photoadducts, which have a drastic effect on
nuclear events (tritiated thymidine incorporation and repair of adducts, for example).
At much higher concentrations, another cellular site is critically damaged, namely the
cell membrane. Given the 8-MOP concentrations typically achieved in patients and the
low effective UVA doses that are actually delivered during photopheresis, it is likely
that most of the time lymphocytes are exposed to doses that fall in an intermediate
region on this curve; that is, 100-200. Under these conditions, nuclear processes which
control cell activity would be crippled. The cell membrane would remain intact,
however, even though molecular modifications, which are the precursors for the
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ultimate disintegration of the membrane, may begin to occur. These cells, when
re-infused in a patient, would be able to circulate for a significant period of time.
During this period, the immune system would have the opportunity to respond to
changes that might have been induced at the cell surface. These changes could be any
one of the following (or some combination): protein photoadducts [23], cell surface
DNA modification (see below), and/or alteration ofcytoskeleton rigidity (see below).
Although the biological effects of 8-MOP plus UVA on cells have usually been
focused on genotoxic events, its successful use in photopheresis raises the question of
whether these effects alone could be responsible. Does the photomodification of cell
surface structures alter the immunological status of cells? In the next section,
little-appreciated effects of 8-MOP and UVA on cellular components other than
nuclear DNA are reviewed.
CELL SURFACE DNA AS A TARGET FOR 8-MOP AND UVA
One additional cellular target on which we have initiated studies is DNA bound to
specific receptors [24] on the surface of human lymphocytes. The surface-bound DNA
(cmDNA) is detectable using selective extraction methods as well as immunofluores-
cence assays. Bennett showed that DNA extracted from the cell membrane constitutes
about 2 percent oftotal cellular DNA. The 260-280 absorbance ratio ranges from 1.48
to 1.60, which is significantly lower than that observed for nuclear DNA (1.8-2.0).
cmDNA isolated from lymphocytes of healthy volunteers and from a cultured
lymphoblastic cell line was 1.7 percent to 2.1 percent ofall DNA with a 260/280 ratio
of 1.48 [Dall'Amico R, Gasparro FP: manuscript in preparation]. At this time, the
origin and the function of cmDNA are unknown; however, the observation that
anti-DNA antibodies interact with the surface of cells from patients with systemic
lupus erythematosus suggests a possible role in autoimmune diseases [25]. We have
studied cmDNA because it is a potential target for modification by photoexcited
psoralen molecules. The binding with psoralens may alter the antigenicity of cmDNA
and lead to immunologically mediated events in patients treated with 8-MOP and
UVA. cmDNA is photomodified by 8-MOP but to a lesser extent than chromosomal
DNA [Dall'Amico R, Gasparro FP: manuscript in preparation]. Lymphocytes incu-
bated for 40 minutes with 100 ng/ml of 8-MOP and exposed to 5 J/cm2 at room
temperature were found to contain 1.8 adducts per million bases in cmDNA and 15.9
in nuclear DNA. The same experiment performed at 40C showed a greater number of
adducts: 7 in cmDNA and 34.4 in nuclear DNA. Shortening the incubation time to
only one minute at 40C did not change the number of adducts in cmDNA (6
adducts/million bases) but halved the number in nuclear DNA (18 adducts/million
bases). Interactions between cmDNA and proteins, which also might explain the low
260-280 ratio, may reduce its ability to be photomodified by psoralens. We have also
used a highly specific monoclonal antibody (8G I) which was previously shown to be
specific for 8-MOP 4',5'-monoadducts to demonstrate that 8-MOP photoadducts
occurred on the surface of lymphocytes [13].
TARGETS OTHER THAN DNA
Microspectrofluorometry ofcells incubated with psoralens indicated that psoralen is
distributed throughout the cell [26]. Although mutagenesis can be attributed to direct
modification of DNA, many of these other biological phenomena cannot be linked to
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DNA modification. Numerous studies support the idea that reactions with many other
target sites account for a large number ofthese effects. Non-DNA effects of psoralens
and UVA have been reviewed recently [27].
Joshi and Pathak have suggested that lipid oxidation is most likely responsible for
the resultant erythema, inflammation, edema, and skin vesiculation [28]. More
recently, however, Ortel and Gange have shown that sub-erythemic doses of UVA can
be administered to skin [29]. After a 24-hour period which allowed the removal ofany
free 8-MOP, an additional UVA exposure induced erythema. This delayed effect was
attributed to the formation of cross-links by persistent monoadducts formed by the
initial exposure to UVA. Although many studies seem to support the idea that
cytotoxicity, mutagenicity, and antiproliferative effects are more likely to arise from
cycloaddition with pyrimidines in DNA, there is still some controversy about the
possible role ofother target molecules.
In our laboratory we have shown that high doses of 8-MOP and UVA lead to
photomodification of membrane-bound proteins. In a polyacrylamide gel analysis of
membrane proteins after treatment with 8-MOP and UVA, 15 radiolabeled bands
were detected. No changes in band position were observed, which would suggest that
protein-protein cross-links were not formed [Dall'Amico R: preliminary results].
Laskin et al. described a specific saturable, high-affinity binding site for psoralens
on the membranes of HeLa cells [30]. It appears that 8-MOP photomodification of
this psoralen receptor leads to an alteration of cell growth and differentiation. These
investigators have proposed a model in which photoalkylation of the psoralen receptor
modulates the epidermal growth factor receptor by inducing the phosphorylation ofthe
latter.
Photomodification of lipid components may alter membrane fluidity and lead to
changes in the nature ofimmunological recognition ofmembrane structures [31]. Such
changes could play a role in the immune recognition of 8-MOP/UVA-modified cells.
NEW PHOTOPHARMACOLOGIC AGENTS
Today two major forms of photochemotherapy are being used clinically. Psoralen
plus UVA, long used to treat dermatologic disorders such as vitiligo and psoriasis, is
now being applied to cutaneous T-cell lymphoma (Heald et al. in this issue),
scleroderma (Rook et al. in this issue), and rheumatoid arthritis (Edelson in this issue).
In oncology, hematoporphyrin derivatives (HpD) form the basis of photodynamic
therapy (PDT) for various solid tumors (e.g., esophageal, bladder, and so on [32]. Both
of these modalities are based on clinical principles developed over the last two decades.
Advances in molecular biology (specifically, the facile production of monoclonal
antibodies and the convenient synthesis ofoligonucleotides) are directing research for
additional photochemotherapies in new and exciting areas. Monoclonal antibodies
tagged with photoactivatable moieties offer the potential of specifically eliminating a
discrete population of cells [33]. Limitless opportunities exist for therapies using
antisense oligonucleotides coupled with photoactivatable groups ([34]; [Gasparro FP:
submitted for publication]). The specificity of DNA base pairing is used to guide
photoactivatable molecules to susceptible sites within specific genes. Once properly
situated, a dose of UVA light is used to activate the chromophore and simultaneously
to inactivate the gene. The ability to select the site of drug activity within a specific
gene with the flick of an electrical switch clearly offers the potential for an infinite
degree ofspecificity.
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SUMMARY
As demonstrated by microspectrofluorometry, psoralens are ubiquitous molecules.
Scattered throughout the cell as they are, they are potential modifiers of various
biological entities when exposed to UVA radiation. Thus, it is not surprising that a
panoply of effects would be observed in a cellular system. Dissecting the respective
roles of these effects will ultimately lead to a deeper understanding of disease
processes, which in turn can result in the development of more precise, scalpel-like
photopharmacologic agents.
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